Form 8-K Sage Therapeutics, Inc. For: Dec 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Sage Therapeutics (SAGE) PT Raised to $193 at Needham & Company
December 7, 2017 4:05 PM ESTNeedham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $193.00 (from $100.00) while maintaining a Buy rating.
Analyst Danielle Brill commented, "Phase 2 data in major depressive disorder (MDD) with oral '217 showed statistically and clinically meaningful reductions on the primary HAM-D... More
Sage Therapeutics (SAGE) PT Raised to $198 at Stifel
December 7, 2017 12:37 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $198.00 (from $105.00) while maintaining a Buy rating.
"Results were notable for clean safety, fast onset and solid durability of effect," Walsh said. "Today's positive results, paired with November's positive P3 brexanolone results (note... More
UPDATE: Sage Therapeutics (SAGE) PT Raised to $280 at RBC Capital; Potential 'Game-Changing' Data and Takeover
December 7, 2017 12:24 PM EST(Updated - December 7, 2017 12:34 PM EST)
(updated to add analyst comments)
RBC Capital analyst Brian Abrahams raised his price target on Sage Therapeutics (NASDAQ: SAGE) to $280.00 (from $137.00) while maintaining an Outperform rating.
Abrahams said the Phase 2 data for '217 "showed a... More
